Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity

被引:80
|
作者
Zhang, Yunfang [1 ]
El-Sikhry, Haitham [1 ]
Chaudhary, Ketul R. [1 ]
Batchu, Sri Nagarjun [1 ]
Shayeganpour, Anooshirvan [1 ]
Jukar, Taibeh Orujy [1 ]
Bradbury, J. Alyce
Graves, Joan P. [2 ]
DeGraff, Laura M. [2 ]
Myers, Page [2 ]
Rouse, Douglas C. [2 ,4 ]
Foley, Julie [2 ]
Nyska, Abraham [2 ,3 ]
Zeldin, Darryl C. [2 ]
Seubert, John M. [1 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada
[2] Natl Inst Environm Hlth Sci, Div Intramural Res, NIH, Res Triangle Pk, NC USA
[3] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
[4] Duke Univ, Med Ctr, Durham, NC USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 2009年 / 297卷 / 01期
基金
加拿大健康研究院;
关键词
cytochrome P-450 2J2; heart; function; ANKYRIN REPEAT PROTEIN; NECROSIS-FACTOR-ALPHA; INDUCED CELL-DEATH; EPOXYEICOSATRIENOIC ACIDS; HUMAN MYOCARDIUM; HEART-FAILURE; CARP GENE; CYTOCHROME-P450; ADRIAMYCIN; METABOLISM;
D O I
10.1152/ajpheart.00983.2008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Zhang Y, El-Sikhry H, Chaudhary KR, Batchu SN, Shayeganpour A, Jukar TO, Bradbury JA, Graves JP, DeGraff LM, Myers P, Rouse DC, Foley J, Nyska A, Zeldin DC, Seubert JM. Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 297: H37-H46, 2009. First published May 8, 2009; doi:10.1152/ajpheart.00983.2008.-Human cytochrome P-450 (CYP)2J2 is abundant in heart and active in biosynthesis of epoxyeicosatrienoic acids (EETs). Recently, we demonstrated that these eicosanoid products protect myocardium from ischemia-reperfusion injury. The present study utilized transgenic (Tr) mice with cardiomyocyte-specific overexpression of human CYP2J2 to investigate protection toward toxicity resulting from acute (0, 5, or 15 mg/kg daily for 3 days, followed by 24-h recovery) or chronic (0, 1.5, or 3.0 mg/kg biweekly for 5 wk, followed by 2-wk recovery) doxorubicin (Dox) administration. Acute treatment resulted in marked elevations of serum lactate dehydrogenase and creatine kinase levels that were significantly greater in wild-type (WT) than CYP2J2 Tr mice. Acute treatment also resulted in less activation of stress response enzymes in CYP2J2 Tr mice (catalase 750% vs. 300% of baseline, caspase- 3 235% vs. 165% of baseline in WT vs. CYP2J2 Tr mice). Moreover, CYP2J2 Tr hearts exhibited less Dox-induced cardiomyocytes apoptosis (measured by TUNEL) compared with WT hearts. After chronic treatment, comparable decreases in body weight were observed in WT and CYP2J2 Tr mice. However, cardiac function, assessed by measurement of fractional shortening with M-mode transthoracic echocardiography, was significantly higher in CYP2J2 Tr than WT hearts after chronic Dox treatment (WT 37 +/- 2%, CYP2J2 Tr 47 +/- 1%). WT mice also had larger increases in beta-myosin heavy chain and cardiac ankryin repeat protein compared with CYP2J2 Tr mice. CYP2J2 Tr hearts had a significantly higher rate of Dox metabolism than WT hearts (2.2 +/- 0.25 vs. 1.6 +/- 0.50 ng.min(-1).100 mu g protein(-1)). In vitro data from H9c2 cells demonstrated that EETs attenuated Dox-induced mitochondrial damage. Together, these data suggest that cardiac-specific overexpression of CYP2J2 limited Dox-induced toxicity.
引用
收藏
页码:H37 / H46
页数:10
相关论文
共 50 条
  • [1] An Emerging Pathway of Doxorubicin Cardiotoxicity Mediated through CYP2J2
    Arnold, William R.
    Das, Aditi
    BIOCHEMISTRY, 2018, 57 (16) : 2294 - 2296
  • [3] Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
    Cheah, Irwin K.
    Tang, Richard M. Y.
    Wang, Xiaoyuan
    Sachaphibulkij, Karishma
    Chong, Suet Yen
    Lim, Lina H. K.
    Wang, Jiong-Wei
    Halliwell, Barry
    ANTIOXIDANTS, 2023, 12 (02)
  • [4] CYP2J2 Overexpression Protects against Arrhythmia Susceptibility in Cardiac Hypertrophy
    Westphal, Christina
    Spallek, Bastian
    Konkel, Anne
    Marko, Lajos
    Qadri, Fatimunnisa
    DeGraff, Laura M.
    Schubert, Carola
    Bradbury, J. Alyce
    Regitz-Zagrosek, Vera
    Falck, John R.
    Zeldin, Darryl C.
    Mueller, Dominik N.
    Schunck, Wolf-Hagen
    Fischer, Robert
    PLOS ONE, 2013, 8 (08):
  • [5] Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane
    Della Torre, P
    Mazué, G
    Podestà, A
    Moneta, D
    Sammartini, U
    Imondi, AR
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 43 (02) : 151 - 156
  • [6] Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane
    Paola Della Torre
    G. Mazué
    Arturo Podestà
    Donatella Moneta
    Umberto Sammartini
    A. R. Imondi
    Cancer Chemotherapy and Pharmacology, 1999, 43 : 151 - 156
  • [7] Mitochondrial elongation confers protection against doxorubicin-induced cardiotoxicity
    He, Weibin
    He, Wenlong
    Chen, Xiaopan
    Zeng, Lin
    Zeng, Lihuan
    Liu, Yuanhui
    He, Pengcheng
    Sun, Zhongchan
    BIOCHEMICAL PHARMACOLOGY, 2024, 229
  • [8] Histamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model
    Sundar Kumar Kondru
    Ajay Godwin Potnuri
    Lingesh Allakonda
    Prasad Konduri
    Molecular and Cellular Biochemistry, 2018, 441 : 77 - 88
  • [9] Histamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model
    Kondru, Sundar Kumar
    Potnuri, Ajay Godwin
    Allakonda, Lingesh
    Konduri, Prasad
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2018, 441 (1-2) : 77 - 88
  • [10] PROTECTION AGAINST DOXORUBICIN-INDUCED CARDIOTOXICITY BY ICRF-187 (DEXRAZOXANE)
    HASINOFF, BB
    FREE RADICAL BIOLOGY AND MEDICINE, 1993, 15 (05) : 510 - 510